Ensysce Biosciences Q3 net loss widens to $82.11 million
ENSC•Ensysce Biosciences reported a third-quarter 2026 net loss attributable to common stockholders of $82.32 million, including a $79.91 million noncash charge related to its Cy Biopharma acquisition. Cash and cash equivalents were $29.67 million at September 30.
1. Quarterly results
Ensysce Biosciences’ third-quarter 2026 net loss attributable to common stockholders widened to $82.32 million. The loss included a $79.91 million noncash charge for acquired in-process research and development related to the Cy Biopharma acquisition. Federal grant funding rose to $2.18 million, and cash and cash equivalents totaled $29.67 million at September 30.
2. Clinical and regulatory updates
UK regulators requested additional information on November 6 for the CY200 Phase 2a trial application, and the company is preparing a response. Enrollment in the final stage of the PF614-MPAR-102 study, which evaluates the opioid candidate’s overdose protection, concluded in August.
